Pneumonitis is an uncommon but potentially fatal toxicity of anti-programmed death-1 (PD-1)/ programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described.
INTRODUCTION
Anti-programmed death-1 (anti-PD-1) and antiprogrammed death ligand 1 (anti-PD-L1) monoclonal antibodies (mAbs) for patients with multiple malignancies are now Food and Drug Administration-approved therapies, which include nivolumab and pembrolizumab for melanoma 1, 2 and non-small-cell lung cancer (NSCLC), [3] [4] [5] [6] nivolumab for renal cell carcinoma 7 and Hodgkin lymphoma, 8 atezolizumab for bladder cancer, 9 and nivolumab plus ipilimumab for melanoma.
10 These agents also have been studied in other diseases [11] [12] [13] along with durvalumab (PD-L1 mAb) and tremelimumab (cytotoxic T-cell lymphocyte-4 [CTLA-4] mAb). 14, 15 One of the remarkable characteristics of anti-PD-1/PD-L1 mAbs is their relatively mild toxicity profile. However, immune-related adverse events can occur and may be severe. 16, 17 Pneumonitis is an immune-related adverse event that accounted for three deaths in an early-phase study with an anti-PD-1 mAb. 18 Pneumonitis is defined as a focal or diffuse inflammation of the lung parenchyma, 19 and its incidence in studies with anti-PD-1/ PD-L1 mAbs has ranged from 0% to 10%. 20 Drug-related pneumonitis can also occur with chemotherapy (docetaxel, 21 gemcitabine, 22 bleomycin 23 ), targeted therapy (epidermal growth factor receptor inhibitors, 24, 25 mammalian target of rapamycin inhibitors 26 ), and radiation therapy. 27, 28 Previous experience with these pneumonitides highlighted that clinical, radiologic, and pathologic characterization may facilitate early recognition, treatment optimization, and improved outcomes. The underlying etiology and mechanisms of pneumonitis associated with anti-PD-1/PD-L1 mAbs are unknown.
With the recent approval of anti-PD-1/PD-L1 mAbs, and several other anticipated indications, use is expected to expand rapidly. A critical need exists to gain familiarity with the clinical features of pneumonitis and to optimize management. The clinical experience of patients with anti-PD-1/PD-L1-associated pneumonitis has not been comprehensively described, and data are sparse with regard to management and outcomes. We describe the clinical, radiologic, and pathologic features and management of 43 cases of pneumonitis as a result of anti-PD-1/PD-L1 mAbs from two separate institutions.
METHODS

Patients
After institutional review board approval, patients treated with anti-PD-1/PD-L1 mAbs either as monotherapy or in combination with anti-CTLA-4 mAb were identified from Memorial Sloan Kettering Cancer Center (MSKCC; January 2009 to September 2014; all advanced cancers) and the Melanoma Institute of Australia (MIA) and affiliated hospitals (January 2013 to August 2015; melanomas only). Anti-PD-1/PD-L1 mAbs were delivered either as part of an institutional review board-approved therapeutic study or as an expanded access program. Patients treated concurrently with chemotherapy, targeted therapy, and immunotherapy other than anti-CTLA-4 mAb, and in whom the treatment received was still blinded, were excluded. Cases were identified and reviewed retrospectively (MSKCC, J.N., H.R., X.H., M.D.H.; MIA, X.W., A.M.M., A.D.G., M.S.C., B.Y.K., G.V.L.). Those with a clear alternative etiology, such as proven malignant lung infiltration or active lung infection, were excluded. Grading was performed by the treating investigator in real time by using Common Toxicity Criteria for Adverse Events (version 4.0); the reported grade refers to the highest grade of pneumonitis experienced.
Methods
For all patients, the treatment regimen received (anti-PD-1/PD-L1 monotherapy or combination with anti-CTLA-4 mAb) and primary tumor site were recorded. In patients with pneumonitis, the following data were collected retrospectively: demographics, prior oncologic therapy, clinical features of pneumonitis, and pneumonitis treatment. Clinical and radiologic outcomes were classified as completely resolved, improved, or worsened. Patients in whom recurrent pneumonitis developed, either with or without drug rechallenge, were noted. Assessment of final clinical outcomes as well as highest grade of pneumonitis included periods of recurrent pneumonitis, if applicable.
Retrospective radiology review of the serial chest computed tomography (CT) scans of patients with pneumonitis was performed in the MSKCC cohort by two independent radiologists (T.I., J.C.) blinded to patient clinical data followed by a consensus read if there was disagreement. Each radiologist described the phenotypic appearance and severity of pneumonitis by using criteria for interstitial lung diseases. [29] [30] [31] When available, chest x-rays at the time of pneumonitis were also reviewed. Lung biopsy specimens obtained at the time of pneumonitis at MSKCC were reviewed by thoracic pathologists (C.L., N.R.) and phenotypically described.
Outcomes Analysis
For all patients treated with anti-PD-1/PD-L1 mAbs, associations between development of pneumonitis and treatment received (anti-PD-1 versus anti-PD-L1 mAb; monotherapy versus combination) and disease type (melanoma versus NSCLC stratified by monotherapy versus combination) were assessed by Fisher's exact test. In patients with pneumonitis, best objective response rates to anti-PD-1/PD-L1 mAbs were calculated with exact 95% CIs. Associations among clinical or radiologic features of pneumonitis, treatment course, and outcomes from pneumonitis treatment were examined. In the radiologic assessment, agreement between individual radiologists was evaluated by Cohen k-coefficient such that a score of 1 indicated complete agreement and 0 indicated no agreement other than what would be expected by chance. All statistical tests were two sided, and 5% was set as the level of significance. Statistical analyses were performed with R version 3.1.1 software (R Development Core Team), including the irr and Hmisc packages.
RESULTS
Incidence of Pneumonitis
Nine hundred fifteen patients received anti-PD-1/PD-L1 mAbs as monotherapy or in combination with anti-CTLA-4 mAb ( Across all evaluable patients (n = 41), the best objective response to therapy was 61% (25 of 41; 95% CI, 45% to 76%; Table 2 ). Among patients with melanoma, the response rate to monotherapy was 73% (11 of 15; 95% CI, 45% to 91%) and to combination therapy, 73% (eight of 11; 95% CI, 39% to 94%).
Clinical Features
Median time to onset of pneumonitis was 2.8 months, with a wide range (9 days to 19.2 months; Fig 1) . Onset tended to be earlier in patients who received combination therapy than in those who received monotherapy (median, 2.7 months [range, 9 days to 6.9 months] v 4.6 months [range, 21 days to 19.2 months]; P = 0.02). Seventeen (40%) patients experienced grade 1 pneumonitis, 14 (33%) experienced grade 2, 10 (23%) experienced grade 3, one (2%) experienced grade 4, and one (2%) experienced grade 5; no difference in distribution of severity between monotherapy and combination therapy was found (Fig 2) .
The most common presenting symptoms of pneumonitis were dyspnea ( More than one half of patients with pneumonitis experienced additional immune-related toxicity (25 of 43 [58%]), which included skin rash (n = 8); colitis (n = 6); hypophysitis, arthritis, and thyroiditis (n = 3 each); and hepatitis, esophagitis, duodenitis, hyperthyroidism, nephritis, myositis, vitiligo, pernicious anemia, and hemolytic anemia (n = 1 each).
Pneumonitis Management
Most patients with grade 1 to 2 pneumonitis were managed as outpatients (25 of 31 [81%]), whereas 19% (six of 31, all grade 2) were hospitalized. All grade 3 and higher cases (n = 12) required hospitalization. In patients with grade 1 pneumonitis, maximum treatment received was drug holding (15 of 17 [88%]) or oral corticosteroids (two of 17 [12%]; Table 3 ). All patients with grade 2 pneumonitis were treated initially with oral/intravenous corticosteroids (n = 14). All patients with grade 3 or higher pneumonitis received oral/intravenous corticosteroids initially (n = 12), five (42%) of whom required additional immunosuppression (three with infliximab and two with both infliximab plus cyclophosphamide).
Among all patients who received corticosteroids (28 of 43 [65%]), 61% (17 of 28) began with oral treatment, and 39% (11 of 28) began with intravenous treatment. For most patients who began oral corticosteroids, this was the maximum immunosuppression used (14 of 17 [82%]), with a median starting dose of prednisone of 50 mg (range, 20 to 80 mg) and median duration of corticosteroid treatment of 68 days (range, 20 to 154 days).
Clinical Outcomes and Mortality Associated With Pneumonitis
Pneumonitis improved/resolved in 88% (37 of 43) of cases (Table 3) , which included all grade 1 (17 of 17), 93% (13 of 14; one patient lost to follow-up and outcome unknown) of grade 2, and 64% (seven of 12) of grade 3 and higher events.
Five (12%) patients clinically worsened during treatment of pneumonitis. All had grade 3 and higher pneumonitis, were treated with additional immunosuppression beyond corticosteroids, and ultimately died. Although one patient's death was solely attributable to pneumonitis, the cause of clinical worsening and death was multifactorial in most cases. Three patients had infections associated with immunosuppression, and one patient had progressive cancer, which seemed to be the most proximal contributors to death.
The patient with grade 5 pneumonitis had initially presented with grade 2 pneumonitis after six doses of anti-PD-1 monotherapy for the treatment of metastatic NSCLC. Oral corticosteroids were initiated, with initial clinical and radiologic improvement. However, pneumonitis recurred during corticosteroid taper and did not improve with high-dose intravenous corticosteroids, infliximab, and cyclophosphamide, and the patient died.
Three patients died as a result of infection in the context of immunosuppression for pneumonitis. One patient received one dose of the anti-PD-1 plus anti-CTLA-4 mAb for melanoma and then was treated for grade 3 pneumonitis with a prolonged course of oral/intravenous corticosteroids over 2 months as well as infliximab. Although the pneumonitis initially seemed to improve, the patient developed pseudomonas pneumonia during corticosteroid treatment and subsequently died. A second patient received two doses of anti-PD-1 mAb for NSCLC and grade 3 pneumonitis developed, which was treated with methylprednisone and infliximab. The patient's condition was complicated by herpes simplex virus 1 sepsis, which resulted in death. A third patient with NSCLC received 38 doses of anti-PD-1 mAb before grade 3 pneumonitis developed that required long-term corticosteroids, infliximab, and cyclophosphamide treatment. The patient died, and on autopsy, fulminant necrotizing fungal pneumonia (mucormycosis) was identified and attributed as the cause of death; no residual cancer was identified. 
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Recurrent Pneumonitis: With or Without T-Cell Checkpoint Rechallenge Eleven patients experienced recurrent pneumonitis during drug holding/corticosteroid therapy after initial clinical improvement (Appendix Table A1 , online only). Of these patients in whom recurrence occurred without drug rechallenge, eight experienced resolution/improvement with further management and three worsened and died despite immunosuppression.
Twelve patients underwent rechallenge with immunotherapy after an initial pneumonitis event (nine grade 1 and three grade 2; nine treated with drug holding only and three treated with corticosteroids for initial event; Appendix Table A2 , online only). All rechallenged cases occurred after complete clinical resolution of pneumonitis. Nine patients did not experience a second pneumonitis event on rechallenge (eight grade 1 and one grade 2), whereas three experienced recurrent pneumonitis after rechallenge of whom one patient initially had grade 1 pneumonitis treated with drug hold only, and had recurrent pneumonitis that was again grade 1 and resolved with drug holding. The other two patients had grade 2 pneumonitis initially, were treated with corticosteroids, and had recurrent grade 2 pneumonitis that again resolved with oral corticosteroids.
Radiologic Features
Radiologic and clinical outcomes of pneumonitis were aligned in all patients who experienced clinical improvement/ resolution (37 of 37), and four of five patients who experienced clinical worsening of their pneumonitis. Serial chest CT scans were available for all MSKCC patients. Radiologic features of pneumonitis were classified into five subtypes (Fig 3) Fig A1, online only) . Cohen k-coefficients were 0.66 for radiologic subtype and 0.88 for radiologic severity grading, respectively. Radiologic subtypes were consistent throughout a patient's clinical course, except in two cases where COP-like pneumonitis evolved into a severe GGO type, and where GGO type developed additional interstitial appearances. COP-like appearance was more common among patients with NSCLC than among patients with other cancers (four of nine v one of 18, P = .03). In addition, patients with the COP-like subtype were more likely to require treatment of pneumonitis (beyond drug hold) than those with other radiologic subtypes (five of five v 11 of 22, P = .06). Chest x-rays obtained at the time of pneumonitis (n = 9) demonstrated possible pneumonitis in 67% of cases (six of nine), possible progressive cancer in 11% (one of nine), and no new radiographic abnormality in 22% (two of nine).
Pathologic Features
Eleven of 27 (41%) patients at MSKCC underwent lung biopsy at the time of pneumonitis (eight bronchoscopic, two core biopsies, one wedge resection; Appendix Table A3 , online only). Histopathologic findings were cellular interstitial pneumonitis (four of 11; Appendix Fig A2A, online only) , organizing pneumonia (three of 11; Appendix Fig A2B) , diffuse alveolar damage (one of 11; Appendix Fig A2C) , and no abnormalities identified (three of 11). The interstitial inflammatory infiltrate included poorly formed granulomas in Abbreviations: COPD, chronic obstructive pulmonary disease; CR, complete response; NSCLC, non-small-cell lung carcinoma; PD, progressive disease; PD-1, programmed death-1; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease. *Never smokers smoked , 100 cigarettes in lifetime. †Assessed with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (n = 27), Immune-Related Response Criteria (n = 10), Cheson criteria (n = 2), International Myeloma Working Group Criteria (n = 1), and modified Severity Weighted Assessment Tool (n = 1); two patients not assessed.
three cases (Appendix Fig A2D) and eosinophils in two cases (Appendix Fig A2E) .
Associations Between Clinical Features and Pneumonitis Outcomes
Worsening clinical outcomes with pneumonitis were more frequent in current versus former smokers (five of 23 v zero of 19, P = .053) and those with underlying lung conditions versus no lung conditions (four of 15 v one of 27, P = .047; Appendix Table A4 , online only). Forced expiratory volume in 1 second and diffusing capacity of lung for carbon monoxide adjusted for hemoglobin were completed in a subset of patients at the time of pneumonitis (16 of 43 and 12 of 43, respectively); no associations between these parameters and clinical outcomes were seen.
DISCUSSION
We describe the first large series of pneumonitis to our knowledge associated with anti-PD-1/PD-L1 mAbs in patients with advanced cancers and comprehensively characterize the clinical, radiologic, and pathologic features, and management of this toxicity. Anygrade pneumonitis developed in approximately 5% of patients treated with anti-PD-1/PD-L1 mAbs, and grade 3 and higher pneumonitis developed in 1%. Pneumonitis was more common in jco.org patients treated with anti-PD-1/PD-L1 mAbs plus anti-CTLA-4 mAb compared with anti-PD-1/PD-L1 monotherapy. Rates of pneumonitis with anti-PD-1 versus anti-PD-L1 mAb in this series were not statistically different; however, larger data sets that include meta-analyses across tumor types are needed to determine conclusively whether a difference exists. Most cases of pneumonitis were mild, which is reassuring, but with the increasing use of anti-PD-1/PD-L1 mAbs in many disease settings, the absolute burden of pneumonitis undoubtedly will rise.
Most patients with pneumonitis were symptomatic at presentation, with one third of cases identified incidentally by imaging. Because timing of pneumonitis onset varied widely, constant vigilance for the signs and symptoms of this toxicity is required.
The majority of patients with pneumonitis in this study were also responders to immunotherapy, although they also had a variety of diseases, treatments, and systems of assessment. Additionally, there may be confounding between increased time on therapy and the association between both risk of pneumonitis and likelihood of benefit from immunotherapy. Nevertheless, it is intriguing to consider a possible mechanistic association between benefit and toxicity with anti-PD-1/PD-L1 agents.
We also describe the varied clinical, radiologic, and pathologic features of anti-PD-1/PD-L1 pneumonitis. Unlike bleomycininduced pneumonitis, which is characterized by specific radiologic appearances 23 and changes in diffusing capacity of lung for carbon monoxide, 32 we did not identify any pathognomonic radiographic or pathologic features of anti-PD-1/PD-L1 pneumonitis. To provide a common language for this toxicity, we describe distinct radiologic phenotypes by CT 26, 33 and found acceptable concordance between independent radiologic reviewers. Because radiology review was only performed in clinically determined pneumonitis cases, the real-world interobserver concordance of radiologic assessments may be lower. Of note, chest x-ray did not detect a new radiographic abnormality in nearly one quarter of pneumonitis cases, which suggests that it may be an inadequate tool for evaluating suspected pneumonitis.
Clinically, nearly all cases of pneumonitis improved/resolved with drug holding and/or immunosuppression. However, some cases worsened and were fatal. In this series, worsening cases were restricted to current and former smokers and were more common in patients with underlying lung conditions; such patients may require particularly careful management. Among patients in whom pneumonitis improved/resolved, 12 (all with grade 1 to 2) underwent rechallenge with anti-PD-1/PD-L1 mAbs, and recurrent pneumonitis occurred in three (25%). This suggests that in mild cases, one may cautiously resume therapy after pneumonitis has improved/resolved and after careful discussion with the patient.
Although most instances of pneumonitis were not severe, five deaths occurred, and in three cases, infection from prolonged immunosuppression contributed to death. No patient who received immunosuppression beyond corticosteroids (infliximab with or without cyclophosphamide) recovered from pneumonitis. Improvement is needed in the choice, dose, and duration of therapies for pneumonitis with consideration of the role of antimicrobial prophylaxis in the context of prolonged immunosuppression.
Drug-induced pneumonitis remains a diagnosis of exclusion and requires consideration of competing diagnoses, including infection and malignant lung infiltration. Diagnostic bronchoscopy with lung biopsy may play an important role in excluding competing diagnoses. We attempted to exclude cases with alternative etiologies and evidence of pulmonary infection or infiltrative cancer. However, the excluded cases may have represented true pneumonitis or mixed presentation. In addition some cases of pneumonitis may not have been detected radiologically, so the true incidence of pneumonitis may be higher than that described here. This series largely comprised patients with melanoma and NSCLC; a larger series that investigates pneumonitis as a result of anti-PD-1/PD-L1 mAbs in other malignancies are needed. Finally, this series describes the features of pneumonitis, but did not seek to identify risk factors for its development, which remains an open question for future investigation. This study fills an important gap in the literature because the only published data on anti-PD-1/PD-L1 pneumonitis are from two small case reports 34, 35 and two larger case series reported at ASCO 2016. 36, 37 Collectively, these reports affirm the variable timing of onset and potential for recurrent pneumonitis during pneumonitis management. Although these studies cannot make firm recommendations about optimal pneumonitis management, grade 1 pneumonitis seems reasonable to treat with drug holding alone, with close clinical and radiologic follow-up (2 to 4 weeks) for resolution/ improvement. If symptoms arise or no radiologic improvement is seen, corticosteroids are appropriate. Grade 2 and higher pneumonitis should be treated with corticosteroids in addition to drug holding, with continued close clinical and radiologic follow-up. Patients in whom worsening pneumonitis develops can be resistant to traditional immunosuppression and may benefit from studies of early additional or new/alternative immunosuppression.
In summary, pneumonitis is an uncommon but potentially serious toxicity that occurs in 5% of patients who receive anti-PD-1/PD-L1 mAbs. Treating physicians should be aware of its diverse clinical, radiologic, and pathologic features and that it may develop at any time during a patient's treatment course. Most cases are mild and managed successfully with favorable outcomes. However, worsening pneumonitis may develop in a subset of patients despite additional immunosuppression, and they may suffer from the immunosuppressive consequences of pneumonitis treatment. Improvements in the treatment and understanding of the biology of pneumonitis are needed to optimize management.
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